Explore 3 Stock Ideas & Industry Insights Download Free Report

Polaryx Therapeutics, Inc. Common Stock

Company price
1.77 USD -0.11 ( 5.85%)
Last update at 2026-11-13T21:00:00Z
VOLUME
9213
Market Cap
101.94M

Momentum Score

…

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.77
Low
1.88
High
52 Week Price Range
1.85
Low
48.91
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Polaryx Therapeutics (NASDAQ: PLYX) is a clinical-stage biopharmaceutical company developing therapeutics; long-term growth drivers include advancement of its clinical pipeline, regulatory milestones, and potential strategic partnerships that could support commercialization. Investors may find the company attractive because clinical progress and proprietary assets may benefit valuation if trials and approvals proceed.

Important risks include trial failures or regulatory delays, ongoing financing needs, limited or no product revenue, and intellectual property or operational uncertainties.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.88
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.10
ROE
-96.56%
Net Debt
-5.14M
ROCE
-162.43%
Diluted EPS TTM
-0.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Income before tax -8.98M -30.36M -3.78M
Net income -8.98M -30.36M -3.78M
Selling general administrative 1.55M 1.54M 1.01M
Ebitda -8.98M -30.36M -3.78M
Operating income -7.82M -4.35M -3.78M
Other operating expenses 7.82M 4.35M 3.78M
Total revenue 0.00M 0.00M 0.00M
Total operating expenses 7.82M 4.35M 3.78M
Total other income expense net -1.16M -26.00M 0.00M
Net income from continuing ops -8.98M -30.36M -3.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 5.42M 5.00M 2.31M
Other current assets 0.03M 0.38M 2.31M
Total liab 0.85M 0.29M 1.04M
Total stockholder equity 4.57M 4.71M 1.28M
Other current liab 0.14M 0.22M 0.44M
Common stock 0.01M 0.02M 0.00M
Capital stock 0.01M 0.02M 0.00M
Retained earnings -99.64M -90.65M -60.29M
Cash 5.14M 4.62M 0.00M
Total current liabilities 0.60M 0.29M 1.04M
Net debt -5.14M -4.62M 0.13M
Short term debt - - 0.13M
Short long term debt - - 0.13M
Short long term debt total - - 0.13M
Other stockholder equity 104.19M 95.35M 61.57M
Total current assets 5.17M 5.00M 2.31M
Accounts payable 0.47M 0.07M 0.47M
Non current assets total 0.25M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Net borrowings 0.00M -0.13M 0.13M
Total cash from financing activities 4.47M 7.19M 0.13M
Net income -8.98M -30.36M -3.78M
Change in cash 0.52M 4.62M -0.04M
Begin period cash flow 4.62M 0.00M 0.05M
End period cash flow 5.14M 4.62M 0.00M
Total cash from operating activities -3.94M -2.57M -0.17M
Issuance of capital stock 4.49M 7.32M 0.00M
Capital expenditures 0.00M 0.00M 0.00M
Change in working capital 0.32M -0.62M 0.37M
Stock based compensation 4.72M 2.40M 3.24M
Other non cash items 4.72M 26.00M -
Free cash flow -3.94M -2.57M -0.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
PLYX
Polaryx Therapeutics, Inc. Common Stock
-0.11
5.85%
1.77 - - - 9.30
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12

Profile*

Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

South Tower, Paramus, NJ, United States, 07652

201 940 7236

2

Name Title Year Born
Mr. Alex Yang J.D., L.L.M. CEO & Chair of Board 1970
Mr. G. Michael Landis CPA CFO & Director 1966
Mr. Andrew John O Chief Investment Officer 1973
Dr. Shrijay Vijayan M.B.A., Ph.D. Chief Scientific & Business Development Officer 1968
Mr. Wuxin Zhu P.M.P., Ph.D. Chief Chemistry, Manufacturing & Controls Officer 1980
Dr. Ralph William Charlton III, M.D. Chief Medical Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…